10-K: Serina Therapeutics Reports Deepening Losses, Secures New Funding Amidst Parkinson's Drug Advancement

Serina Therapeutics, a clinical-stage biotechnology company, reported a significant increase in net losses for 2025, alongside ongoing concerns about its ability to continue as a going concern, despite advancing its lead Parkinson's disease candidate, SER-252, into Phase 1b clinical trials and securing new capital.

Summary

• Reported a net loss of $19.2 million for the year ended December 31, 2025, an increase from $11.2 million in 2024.
• Accumulated deficit reached $63.5 million as of December 31, 2025.
• Cash and cash equivalents stood at $3.1 million as of December 31, 2025, down from $3.672 million in 2024.
• Received FDA clearance for the Investigational New Drug (IND) application for SER-252, its lead product candidate for advanced Parkinson's disease, in January 2026.
• Enrolled and dosed the first patient in the Phase 1b clinical trial for SER-252 in February 2026.
• Entered into a non-exclusive license agreement with Pfizer in October 2023 for its POZ polymer technology in lipid nanoparticle drug delivery formulations, including an upfront payment of $3 million and potential milestone payments and royalties.
• Sold its subsidiary, UniverXome, to Juvenescence in December 2024, which included the assumption of $11.3 million in secured debt by Juvenescence.
• Raised $4.9 million in net proceeds from a private placement of Series A Convertible Preferred Stock in April 2025.
• Utilized an At-The-Market (ATM) program, selling 0.5 million shares for gross proceeds of $2.8 million in 2025, and an additional 3.0 million shares for $10.0 million gross proceeds in 2026.
• Drew down the first tranche of $5.0 million under a $20 million unsecured convertible note in September 2025, with the note subsequently amended in March 2026.
• Completed a private placement of common stock and pre-funded warrants in March 2026, raising $16.0 million in gross proceeds initially, with potential for up to $33.3 million from warrant exercises.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative filing due to the significant increase in net losses, growing accumulated deficit, and explicit 'going concern' doubt. While IND clearance and new funding are positive operational and financing developments, they do not fully offset the underlying financial instability and the NYSE American listing deficiency.

Positives

• FDA clearance of the IND application for SER-252 in January 2026 allows progression to clinical trials for advanced Parkinson's disease.
• Initiation of the Phase 1b clinical trial for SER-252 in February 2026 marks a significant step in its lead development program.
• Preclinical studies for SER-252 in monkeys suggest potential for twice-weekly subcutaneous injection, continuous apomorphine delivery, and no skin liabilities, addressing a key limitation of existing therapies.
• The non-exclusive license agreement with Pfizer for POZ polymer technology in lipid nanoparticle drug delivery provides an upfront payment of $3 million and potential future milestone and royalty revenues (2.75%-3.5% tiered).
• The POZ technology offers advantages over PEG, including easier synthesis, stability, higher drug loading, programmable release kinetics, and no accumulation in tissues in preclinical studies.
• SER-214 Phase Ia study demonstrated the POZ technology's proof-of-principle, showing continuous drug delivery of rotigotine in the therapeutic window and a dose-dependent improvement in UPDRS (Part III) scores in early Parkinson's patients.
• Successful remediation of previously reported material weaknesses in internal control over financial reporting as of December 31, 2025.

Negatives

• Net loss increased significantly to $19.2 million in 2025 from $11.2 million in 2024.
• Accumulated deficit grew to $63.5 million as of December 31, 2025.
• Cash and cash equivalents decreased to $3.1 million as of December 31, 2025, from $3.672 million in 2024.
• Management believes current cash and cash equivalents are not sufficient to fund operations for the next twelve months, raising substantial doubt about the company's ability to continue as a going concern.
• The company has a history of operating losses and has not generated any revenue from product sales to date, with profitability not anticipated for several years, if ever.
• The NYSE American notified the company in January 2026 that it no longer met the $4 million stockholders' equity requirement, necessitating a compliance plan by July 9, 2027.
• SER-214, a proof-of-principle product candidate, is not being advanced internally beyond Phase Ia and will be sought for out-licensing.

Risks

• History of operating losses and expectation of continued losses for the foreseeable future, with inability to predict future profitability.
• Need for additional financing to execute the operating plan and continue as a going concern, with no assurance of obtaining capital on favorable terms or at all.
• Product candidates are at an early stage of development and may not be successfully developed or commercialized, with failure possible at any stage of preclinical or clinical development.
• Preliminary results from nonclinical studies and clinical trials may change as more data becomes available and undergoes verification.
• FDA or comparable foreign regulatory authorities may disagree with regulatory plans, potentially delaying or preventing approval of product candidates.
• Failure of the POZ technology to successfully identify and advance product candidates could significantly harm the business.
• Product candidates may not receive expedited designations (e.g., fast track, breakthrough therapy) or such designations may not lead to faster development or approval.
• Inability to obtain approval via the accelerated approval pathway may require additional studies, and accelerated approval could be withdrawn.
• Difficulties in enrolling patients in clinical trials could delay or adversely affect clinical development activities.
• Product candidates may cause unacceptable adverse events or have other properties that delay or prevent regulatory approval or commercialization.
• Reliance on contract manufacturing organizations (CMOs) for pharmaceutical supplies introduces risks of delays, quality issues, and reduced control over manufacturing.
• Reliance on third parties to conduct nonclinical studies and clinical trials means less control over timing and quality, potentially leading to delays or unsuccessful programs.
• Substantial product liability or indemnification claims could arise from clinical testing of product candidates.
• Failure to achieve broad market acceptance among physicians, patients, and payors for any approved product candidates would limit revenues.
• Inability to establish sales and marketing capabilities or secure third-party agreements for commercialization could hinder success.
• Significant competition in a rapidly changing technological environment, with competitors potentially achieving approval sooner or developing superior therapies.
• Approved products may be subject to unfavorable pricing regulations, reimbursement practices, or healthcare reform initiatives.
• Inability to protect and/or enforce intellectual property rights, including patents and trade secrets, could harm the competitive position.
• Litigation to enforce or defend intellectual property rights, or against infringement claims by third parties, could be costly and time-consuming.
• Changes in patent law could diminish the value of patents, and patent terms may be inadequate to protect competitive position.
• Unfavorable global economic conditions, including geopolitical instability and inflationary pressures, could adversely affect the business.
• U.S. federal income tax reform, including changes to R&D expensing and the Inflation Reduction Act, could adversely affect financial condition.
• Conflicts of interest may arise from the relationship with Juvenescence, a significant stockholder with substantial influence over the company.

Future Outlook

Serina Therapeutics expects to continue incurring substantial expenditures and operating losses for the foreseeable future as it advances its product candidates through clinical development and seeks regulatory approvals. The company anticipates increased expenses for research and development, hiring additional personnel, and public company compliance. Future funding will be sought through equity offerings, debt financings, and collaborations, with no product sales expected for several years. The company aims to expand its POZ platform applications through internal development and partnerships, particularly in CNS disorders and LNP-delivered RNA therapeutics.

Management Comments

• Management believes that its cash and cash equivalents are not expected to be sufficient to satisfy anticipated operating and other funding requirements for the twelve months from the issuance of these consolidated financial statements, raising substantial doubt about the company's ability to continue as a going concern.
• Management believes the SER-214 program, while not being advanced internally, provided data important to the development of a POZ dopamine agonist conjugate to enable Continuous Dopaminergic Stimulation (CDS) in Parkinson's patients, leading to SER-252.
• Management believes that SER-252 may allow some patients to titrate completely off L-DOPA, thus simultaneously addressing the LIDS that is associated with prolonged use.
• Management believes that SER-252 may be administered in the patient's home without the need for a healthcare provider, and patients may not need to continue therapy with levodopa (levodopa sparing strategy).

Industry Context

StockSavvy.ai notes that Serina Therapeutics operates in the highly competitive biotechnology sector, specifically targeting neurological diseases like Parkinson's and leveraging its proprietary POZ drug delivery technology. The focus on Continuous Dopaminergic Stimulation (CDS) for Parkinson's disease addresses a significant unmet need, as current therapies like AbbVie's Duopa and Vyalev, while effective, have limitations such as invasiveness, daily administration, or severe skin reactions. Serina's preclinical data suggesting a twice-weekly subcutaneous injection without skin liabilities for SER-252 positions it as a potentially differentiated offering against competitors like Supernus's Apokyn and AbbVie's infusion therapies. The company's exploration of POZ-lipids as an alternative to PEG-lipids in lipid nanoparticles (LNPs) for RNA vaccines and therapeutics aligns with a broader industry trend to overcome immunogenicity concerns associated with PEG, particularly highlighted by COVID-19 vaccines. This strategy could open up significant licensing opportunities in infectious diseases, cancer immunology, and gene therapy, where LNP-delivered RNA therapeutics are a rapidly growing field with over 1,200 candidates in development.

Comparison to Industry Standards

• Serina's SER-252 aims to provide Continuous Dopaminergic Stimulation (CDS) for Parkinson's disease, similar to AbbVie's Duopa (levodopa-carbidopa intestinal gel infusion) and Vyalev (foslevodopa-foscarbidopa subcutaneous infusion), but with the potential advantage of less frequent, non-invasive subcutaneous injections and reduced skin reactions, which are significant issues for Apo-go (apomorphine) and Onapgo (apomorphine) infusion therapies.
• The preclinical data for SER-252 in monkeys, showing continuous delivery of apomorphine with no skin liabilities, compares favorably to the known severe skin reactions (ulceration, draining abscesses, nodule formation in ~40% of patients) associated with subcutaneous Apo-go administration.
• The Phase Ia study of SER-214 demonstrated that a single weekly injection of 200 mg SER-214 approximated the plasma levels of rotigotine from a daily 3 mg Neupro patch, suggesting a significant improvement in dosing convenience compared to existing transdermal patches.
• Serina's POZ technology is presented as an alternative to polyethylene glycol (PEG) for drug conjugation, aiming to address PEG's limitations such as low drug loading, susceptibility to air oxidation, and accumulation in tissues. This positions Serina against companies utilizing PEGylation for drug delivery, a technique successfully employed in over 30 FDA-approved drugs.
• The development of POZ-lipids for lipid nanoparticles (LNPs) directly competes with PEG-lipids used in currently approved mRNA vaccines (e.g., Pfizer/BioNTech and Moderna COVID-19 vaccines), aiming to mitigate potential anti-PEG antibody issues and accelerated blood clearance.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings as of the date of the report.

Related Party Transactions

• Juvenescence (UK) Limited is a significant stockholder, owning approximately 33.0% of outstanding common stock as of March 1, 2026, and holds warrants to purchase additional shares.
• Two members of the Board of Directors are affiliated with Juvenescence (Executive Chairman and Co-Founder, and Chief Executive Officer).
• In December 2024, the company sold its subsidiary UniverXome to Juvenescence, which included the assumption of approximately $11.3 million in secured debt (2022 Secured Note and 2023 Secured Note) owed by UniverXome to Juvenescence.
• In April 2025, Juvenescence participated in a private placement of Series A Convertible Preferred Stock, contributing to the $4.9 million net proceeds.
• In September 2025, a member of the Board of Directors (Gregory Bailey, also Co-Founder of Juvenescence) provided a $20 million unsecured convertible note, with the first tranche of $5.0 million drawn.
• In March 2026, a private placement of common stock and pre-funded warrants was led by a member of the company's Board of Directors (Gregory Bailey), providing $16.0 million in initial gross proceeds and potential for up to $33.3 million from redeemable warrants. In connection with this, the 2025 Convertible Note was amended to remove further borrowing obligations.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing capital raises (private placements, ATM offerings, warrant exercises) and potential further dilution if the company needs more funding. The NYSE American listing deficiency could negatively impact share price and liquidity. The 'going concern' doubt presents a substantial risk to investment value.
• **Employees:** The company expects to increase headcount to support development, which could lead to new opportunities but also potential pressure due to financial instability and the need for continued funding.
• **Customers/Patients (future):** Potential for new, improved treatments for Parkinson's disease (SER-252) and other indications, offering better efficacy, safety, and convenience compared to existing therapies. However, early-stage development means these benefits are not yet realized.
• **Partners (e.g., Pfizer, Enable):** Pfizer's licensing agreement provides validation and potential revenue streams. The partnership with Enable Injections for SER-252 delivery could enhance product appeal. These relationships are crucial for Serina's strategic growth and commercialization efforts.
• **Creditors:** The company's 'going concern' doubt and reliance on future financing pose risks to creditors, although recent capital raises provide some short-term relief.

Next Steps

• Continue to advance SER-252 through Phase 1b clinical trials for advanced Parkinson's disease.
• Seek to create economic and strategic value through POZ LNP licensing and partnerships across multiple RNA-based therapeutic indications.
• Seek to create economic and strategic value for other applications of the POZ platform, including Antibody Drug Conjugates (ADCs).
• Continue to expand upon applications of the POZ platform to enable additional payloads and product opportunities.
• Continue to expand a network of academic and biopharmaceutical collaborations and commercial partnerships.
• Address the NYSE American listing deficiency by demonstrating intent to regain compliance with stockholders' equity requirements by July 9, 2027.
• If Phase I for SER-252 is successful, plan a meeting with the FDA to aid in the design of a Phase II study.
• Potentially out-license SER-214 for further development.

Key Dates

Recommendation

Despite positive clinical advancements like the IND clearance for SER-252 and strategic partnerships, Serina Therapeutics faces severe financial challenges, including significant and increasing net losses, a substantial accumulated deficit, and explicit 'going concern' doubt from management and auditors. The NYSE American listing deficiency further highlights the precarious financial position. While recent capital raises provide some liquidity, the continuous need for funding and the early stage of its product pipeline (with no product sales anticipated for several years) indicate high risk and potential for further dilution. A seasoned investor would likely view the fundamental financial instability and the high execution risk of early-stage biotech development, compounded by the listing concerns, as outweighing the promising but distant clinical prospects, leading to a 'sell' recommendation.

Keywords

Serina Therapeutics, POZ technology, Parkinson's disease, SER-252, apomorphine, drug delivery, biotechnology, clinical-stage, SEC filing, 10-K, financial results, operating losses, going concern, capital raise, warrants, IND clearance, Phase 1b, Pfizer license, lipid nanoparticles, RNA therapeutics, intellectual property, biopharmaceutical